HDAC9 in Insulin Resistance: An Update on Epigenetic Mechanisms, Inflammatory Crosstalk, and Therapeutic Potential
Diabetes, Metabolic Syndrome and Obesity · 2026-08 · Volume 19 · 1-17
DOI: 10.2147/dmso.s622182 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2026-08. Verfasst von Lingzhen Meng und 2 weiteren Autor:innen. Beteiligte Einrichtung: General Medical Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- General Medical Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
- Endocrinology Department, The Second Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
ORCID-Profile: Lingzhen Meng, Jing Liu, Zhihong Liu
Zitieren
APA
Meng, L., Liu, J., & Liu, Z. (2026). HDAC9 in Insulin Resistance: An Update on Epigenetic Mechanisms, Inflammatory Crosstalk, and Therapeutic Potential. Diabetes, Metabolic Syndrome and Obesity, Volume 19, 1-17. https://doi.org/10.2147/dmso.s622182
Vancouver
Meng L, Liu J, Liu Z. HDAC9 in Insulin Resistance: An Update on Epigenetic Mechanisms, Inflammatory Crosstalk, and Therapeutic Potential. Diabetes, Metabolic Syndrome and Obesity. 2026;Volume 19:1-17. doi:10.2147/dmso.s622182
BibTeX
@article{Meng2026,
author = {Meng, Lingzhen and Liu, Jing and Liu, Zhihong},
title = {HDAC9 in Insulin Resistance: An Update on Epigenetic Mechanisms, Inflammatory Crosstalk, and Therapeutic Potential},
journal = {Diabetes, Metabolic Syndrome and Obesity},
year = {2026},
volume = {Volume 19},
pages = {1--17},
doi = {10.2147/dmso.s622182}
}
EUVIMED